Smarter Site Feasibility Strategies for Predictable Enrollment in Late-Stage Oncology Trials

Sandra Olthof, MSc, is the Global Operations Head of Oncology/Hematology at Allucent, where she leads cross-functional project teams, manages oncology and hematology portfolios and drives process optimization and client satisfaction within Clinical Trial Operations. With over 15 years of experience in clinical oncology, she has successfully led global Phase I–IV trials across immuno-oncology and hematologic oncology, ensuring operational excellence and high-quality delivery.

Almenia Garvey is the Senior Director of Global Feasibility/Site Engagement at Allucent. With over 25 years of experience in clinical research, Almenia has been involved in numerous projects that integrate healthcare and technology, such as EHR2EDC. Her expertise lies in site selection strategy, investigator identification and investigator relationship management. Almenia serves on the Board of Directors for Nvolve, a non-profit organization dedicated to preparing young women for STEM careers. Additionally, she contributes her expertise as an advisory board member for CISCRP (Center for Information & Study on Clinical Research Participation).

Kitty Oudijk, MSc, is the Associate Director of Patient Engagement at Allucent. With over 18 years of professional experience in the field of clinical research, Kitty is responsible for managing the patient recruitment strategy from proposal to study close-out, including creating the strategic plan and tactics that will be utilized. She oversees the coordination and management of the PE strategy by coordinating all aspects from in-house material creation to vendor management of PE vendors, ensuring the recruitment targets are met and preferably achieved ahead of target. Her focus is on projects in various indications with a range of investigational drugs, from early Phase/FIH to large international Phase III studies.